DAVID PARK to Programmed Cell Death 1 Receptor
This is a "connection" page, showing publications DAVID PARK has written about Programmed Cell Death 1 Receptor.
Connection Strength
0.055
-
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial. Nat Med. 2026 Mar; 32(3):992-1001.
Score: 0.055
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.